Publicaciones
2021
Central Activation of Alpha7 Nicotinic Signaling Attenuates LPS-Induced Neuroinflammation and Sickness Behavior in Adult but Not in Aged Animals. Molecules. Apr. 2021. DOI: 10.3390/molecules26082107
2020
9. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. Pharmacological Research. Feb 2020. DOI: 10.1016/j.phrs.2019.104597
10. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. Eur. J. Med. Chem. Mar 2020. DOI: 10.1016/j.ejmech.2020.112090
11. Optical control of muscular nicotinic channels with azocuroniums, photoswitchable azobenzenes bearing two N-methyl-N-carbocyclic quaternary ammonium groups. Eur. J. Med. Chem. May 2020. DOI: 10.1016/j.ejmech.2020.112403
12. Aza-CGP37157-lipoic hybrids designed as novel Nrf2-inducers and antioxidants exert neuroprotection against oxidative stress and show neuroinflammation inhibitory properties. Drug Development Research. May 2020. DOI: 10.1002/ddr.21618
13. NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. Jun 2020. DOI: 10.3390/biom10060904
14. Aging and Progression of Beta-Amyloid Pathology in Alzheimer’s Disease Correlates with Microglial Heme-Oxygenase-1 Overexpression. Antioxidants. Jul 2020. DOI: 10.3390/antiox9070644
Perspectives on the Clinical Development of NRF2-Targeting Drugs. Handbook of Experimental Pharmacology (Chapter). Aug 2020. DOI: 10.1007/164_2020_381
15. When It Comes to an End: Oxidative Stress Crosstalk with Protein Aggregation and Neuroinflammation Induce Neurodegeneration. Antioxidants. Aug 2020. DOI: 10.3390/antiox9080740
Protective role of microglial HO-1 blockade in aging: Implication of iron metabolism. Redox Biology. Nov 2020. DOI: 10.1016/j.redox.2020.101789
16. Perspectives on the Clinical Development of NRF2-Targeting Drugs. Handbook of Experimental Pharmacology (Chapter). Aug 2020. DOI: 10.1007/164_2020_381
2019
6. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. Jan 2019. DOI: 10.1038/s41573-018-0008-x
7. New flavonoid – N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties. J. Enzyme Inhib. Med. Chem. Mar 2019. DOI: 10.1080/14756366.2019.1581184
8. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev. Jul 2019. DOI: 10.1155/2019/9372182
2018
1. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biol. Apr 2018. DOI: 10.1016/j.redox.2017.10.010.
2. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacol Rev. April 2018. DOI: 10.1124/pr.117.014753
3. Transcription factor NFE2L2/NRF2 modulates chaperone-mediated autophagy through the regulation of LAMP2A. Autophagy. Jul 2018. DOI: 10.1080/15548627.2018.1474992
4. Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy. Redox Biol. Sep 2018. DOI: 10.1016/j.redox.2018.07.006
5. Multi-target-directed ligands for Alzheimer´s disease: discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. Eur. J. Med. Chem. Oct 2018. DOI: 10.1016/j.ejmech.2018.07.056
